Application of Gypensapogenin B in medicament for treating rheumatoid arthritis

An arthritic and rheumatoid technology, applied in the application field of Gypensapogenin B in the treatment of rheumatoid arthritis drugs, can solve the problems of poor action selectivity, easy to induce infection, damage to gastrointestinal mucosa, etc.

Active Publication Date: 2014-04-16
启东市天汾电动工具技术创新中心
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin B in medicament for treating rheumatoid arthritis
  • Application of Gypensapogenin B in medicament for treating rheumatoid arthritis
  • Application of Gypensapogenin B in medicament for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: the preparation of the compound Gypensapogenin B tablet involved in the present invention:

[0012] Take 20 grams of compound Gypensapogenin B, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press machine.

Embodiment 2

[0013] Embodiment 2: the preparation of the compound Gypensapogenin B capsules involved in the present invention:

[0014] Take 20 grams of compound Gypensapogenin B, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.

[0015] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0016] Experimental example 1, the influence of Gypensapogenin B of the present invention on rat adjuvant arthritis

[0017] Grind Mycobacterium casei (Difco) and mix it with liquid paraffin to make 10mg / ml, and make Freund's complete adjuvant after autoclaving. Male SD rats were intradermally injected with 50ul of the above-mentioned adjuvant in the right hind paw, and at the same time, injected 50ul intradermally at the tail about 3cm away from the base of the tail. The difference of , represents the degree of swelling. On the 16th day after the adjuvant injection, the left hind paw of the rats was obviously swollen, and the rats were divided into groups according to the degree of swelling and body weight. The experimental group was orally given Gypensapogenin B 5.0, 10.0, 20.0 mg / kg of the present invention, and the positive control group was orally given diclofenac 10 mg / kg, the control group was given equal volume of distilled water, once a day, for 7 consecutive days, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to Gypensapogenin B for treating immune inflammation and preparing a medicament for treating rheumatoid arthritis. By using terfenadine and diclofenac sodium as contrasts, the Gypensapogenin B has definite treatment effect. The application of the Gypensapogenin B in preparation of the medicament for treating rheumatoid arthritis is disclosed for the first time, the skeleton type is a brand-new skeleton type, the Gypensapogenin B has unexpected strong inhibiting activity on the rheumatoid arthritis, the probability of giving any revelation by other compounds does not exit, and the Gypensapogenin B has predominant substantial characteristics and obviously has a remarkable progress in prevention and treatment of the rheumatoid arthritis.

Description

technical field [0001] The invention relates to the application of Gypensapogenin B in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a clinical common disease and frequently-occurring disease. Rheumatoid arthritis belongs to autoimmune disease and belongs to the category of immune inflammation. At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection. Therefore, compounds with well-defined components, controllable quality, safety and high efficiency have potential value in the development of drugs for rheumatoid arthritis. [0003] The compound Gypensapogenin B involved in the present invention was published in 2012 (Li, N. et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/58A61P19/02A61P29/00
Inventor 黄晨俞骁吴俊华
Owner 启东市天汾电动工具技术创新中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap